Global stock

NYSEUSD

Hims & Hers Health

HIMS

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

32/ 100

Overall score·HIMS

Current price

27.71USD

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 22.69 a P/S 2.59 naznačují, že trh očekává růst, ale výrazné P/B 20.60 a záporné zisky ukazují na překonání fundamentů. Růst tržeb 38.2% YoY je pozitivní, ale marže a ROE jsou silně negativní, což tlumí pozitivní dopad růstu. Technická situace ukazuje na pokles ceny – 7d -11%, 30d -23.5% a cena pod 50denním klouzavým průměrem, což smeruje k oslabení.

§ Outlook vs S&P 500Next 12 months

Probably not

Estimated chance of beating the index: about 34%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Hims & Hers Health (HIMS) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

32/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

32/100

Slightly negative signal based on current news, price action and the economy.

41/100

A lower score means the stock is expensive relative to the company's earnings and assets.

184% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+38%

How fast the company's revenue grows year on year.

10/100

How much the company earns from each unit of revenue and from invested capital.

15/100

Debt level, share-price volatility and how resilient the company is in bad times.

40/100

AI estimate of management quality, execution and capital allocation.

25/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Spoluzakladatel Andrew Dudum je předsedou představenstva a CEO; Mike Chi působí jako provozní ředitel, Mohamed ElShenawy jako technologický ředitel a Soleil Teubner Boughton jako právní ředitelka a tajemnice společnosti. Strategie staví na digitální zdravotní platformě, předplatném a rozšiřování nabídky léčby a online péče.

Articles about Hims & Hers Health, in Czech (1)

AI a datová infrastruktura táhnou akcie IBM, Hims & Hers i průmyslové firmy

Dnešní růst akcií IBM, Hims & Hers a průmyslových firem je výsledkem rostoucí poptávky po AI a datové infrastruktuře, která posiluje technický i průmyslový sektor.

27 May 2026· 4 min

§ Upcoming results

9 November 2026

in 13 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Hims & Hers Health (HIMS)?

Hims & Hers Health (HIMS) is a global stock traded on NYSE. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Hims & Hers Health price today?

As of 23 October 2026, Hims & Hers Health trades at about 27.71 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Hims & Hers Health?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Hims & Hers Health pay a dividend?

Hims & Hers Health either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Hims & Hers Health a good investment in 2026?

Our AI signal currently rates Hims & Hers Health as slightly negative (score 32/100). Financial health comes out at 32/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 184 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Hims & Hers Health

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly negative

Earnings in 13 days

On 9 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Older news

Signal 25/10, 03:01

Zpráva z 25. října uvádí za Q2 2026 růst tržeb na 753,2 mil. USD, ale také čistou ztrátu 86,3 mil. USD; další výsledky ukážou, zda se ziskovost obnoví.

Slabé momentum, klesající trend a pokles ceny za 7 i 30 dní posilují krátkodobě negativní obraz. Růst tržeb a širší nabídka péče poskytují protiváhu, ale tlak na marže a právní nejistota zůstávají.

Risks: Návrat k růstu zisku a stabilních marží by oslabil negativní výhled; prohlubující se ztráty či další právní tlak by jej naopak potvrdily.

More about the signal

Risks: Návrat k růstu zisku a stabilních marží by oslabil negativní výhled; prohlubující se ztráty či další právní tlak by jej naopak potvrdily.

Signal history· 2

24/1009:0139 · Slightly negative
Hims & Hers žádá soud o zamítnutí stížnosti FTC; akcie zároveň zaostaly za trhem. Příznivé rozhodnutí by právní tlak zmírnilo, nepříznivé jej může prohloubit.
23/1005:0147 · Neutral
Hims & Hers žádá o zamítnutí žaloby FTC týkající se ochrany soukromí a předplatného; právní nejistota by polevila při příznivém rozhodnutí soudu.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued184% above fair value

9.76

range 8.1 – 11.9

Current price

27.71 USD

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

9.76 USD

range 8.1 USD – 11.9 USD

: 15.0%
: 12.0%
: 0.55 USD

Free cash flow was below half of earnings last year because of heavy investment, so the model starts from earnings without one-off items (capped at operating cash flow).

Růst 15 % p.a. zohledňuje rychlý růst tržeb, ale je konzervativnější než jeho současné tempo kvůli nejisté ziskovosti. Diskontní sazba 12 % odráží vysokou betu a zvýšené riziko; terminální růst 2,5 % odpovídá dlouhodobému růstu ekonomiky.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 16 of 18

Valuation score

1/ 6

5/6 tests available

1. Below DCF fair value

183.9% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

56% above the 1-year low (14.52 USD to 38.28 USD), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG 2.2; a lower value means cheaper growth.

6. Analyst price target

12.4% vs. the current price, 13 analysts.

Price vs DCF

Current price

27.71 USD

Low 8.12 USDHigh 11.87 USD

Current priceDCF midpoint: 9.76 USD

Price vs analyst target

Current price

27.71 USD

Low 23.00 USDHigh 42.00 USD

Current priceAverage: 31.15 USD

DCF gap

above range

183.9% above the DCF midpoint (9.76 USD).

Analyst target

+12.4%

Average target 31.15 USD vs. price 27.71 USD.

Analyst consensus

Target range

23.00 USD - 42.00 USD

Coverage

13 analysts

Analyst consensus

2.8 / 5

Changes 180 d

+3 / -1

EPS next year

134.7%

Revenue next year

24.9%

Valuation multiples

22.7

20.6

2.6

-725.2

2.2

52-week range56% above the low

14.52 USD38.28 USD

38.0%

-5.5%

-32.0%

Price vs 50D-12.7%

Price vs 200D-5.3%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

mixed

Management má zkušenosti v digitálním zdravotnictví, ale governance rizika a vysoký dluh snižují důvěru v efektivní alokaci kapitálu.

weak

Moat je omezený; platforma má síťové efekty a značku, nicméně konkurence je silná a switching costs jsou nízké.

Information

Type: Global stock
Symbol: HIMS
Exchange: NYSE
Currency: USD
Sector: Healthcare
: 6.7B USD
: 477.1 %
: 2.42

§ Risk profile

Pro českého investora jsou významná rizika vysokého ocenění a kolísavosti růstové akcie, změn americké regulace telemedicíny a léčiv a pohybu kurzu USD/CZK. Ztráty může prohloubit také konkurence a závislost na placené zákaznické akvizici.

Ask the AI about Hims & Hers Health All signals